Journal Article Summary
The article discusses bilastine, a new oral antihistamine that does not cause sedation, and its effectiveness in treating allergic rhinoconjunctivitis and chronic urticaria. This topic is significant because allergic conditions can severely impact quality of life, and existing treatments may not adequately address symptoms, particularly nasal obstruction. Bilastine's introduction offers a potential alternative for patients who struggle with traditional antihistamines that may not provide sufficient relief.
The study reviewed various clinical trials that assessed the efficacy of bilastine compared to other antihistamines like desloratadine and cetirizine. The trials included participants aged 12 to 70 and demonstrated that a daily dose of 20 mg of bilastine effectively reduced symptoms of allergic rhinoconjunctivitis and chronic urticaria. The results indicated that bilastine was comparable to other antihistamines in relieving symptoms, including nasal and eye discomfort, although one study did not show significant differences in efficacy. Overall, bilastine was found to be well-tolerated, with side effects similar to those of other antihistamines.
Despite its promising results, the article notes several limitations, including the fact that most studies were sponsored by the drug's manufacturer, which could introduce bias. Additionally, there is a lack of research on bilastine's effects in children under 12 and its long-term impact on quality of life. Patients should consult with healthcare professionals to discuss the suitability of bilastine for their specific conditions, especially considering the recommended timing for taking the medication in relation to meals, which may affect its absorption.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Wolthers Ole D.. Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria. BioMed Research International 2013. DOI: 10.1155/2013/626837. PMID: 23956994. PMCID: PMC3728546.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby --- Over The Counter
Loratadine 10 mg — 300 Count Bottle — Generic For Claritin — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
